MedTrace Logo

Preoperative Bexarotene Treatment for Cushing's Disease

NCT00845351 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2011-05-30

No results posted yet for this study

Summary

The objective of this pilot study is to establish the safety and tolerability of short-term therapy with bexarotene in patient's with Cushing's disease, and study the clinical, biochemical, and cellular effects of a preoperative five-day course of bexarotene in these patients before undergoing transsphenoidal surgery.

Conditions

  • Cushing's Disease

Interventions

DRUG

Bexarotene

bexarotene at 300 mg/m2/day

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Mary Lee Vance, MD · University of Virginia

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00845351 on ClinicalTrials.gov